- Open
- 1600.00
- High
- 1623.00
- Low
- 1600.00
- Close
- 1621.00
- Change
- +7.00 (0.43%)
- Volume
- 181,794
| 28 Jul 2026 | 15:44:35 | Holding(s) in Company |
| 27 Jul 2026 | 11:48:25 | Transaction in Own Shares |
| 24 Jul 2026 | 11:25:35 | Holding(s) in Company |
| 23 Jul 2026 | 15:21:01 | Holding(s) in Company |
| 18 Mar 2026 | 2025 Annual Report and Accounts | |
| 19 Mar 2025 | 2024 Annual Report and Accounts | |
| 22 Mar 2024 | 2023 Annual Report and Accounts |
Hikma Pharmaceuticals plc is a global pharmaceutical company that develops, manufactures, and markets a wide range of generic, specialty, and branded medications. Its operations are divided into three main segments: Injectables, which supplies hospitals with generic and specialty injectable products; Branded, which offers branded generics and in-licensed patented products primarily in the MENA region; and Hikma Rx, which provides oral and respiratory generic products to the North American retail market. Hikma operates manufacturing facilities and R&D hubs across North America, Europe, and the MENA region, serving healthcare providers and patients in over 50 countries.
| 28 Jul 2026 | 15:44:35 | Holding(s) in Company |
| 27 Jul 2026 | 11:48:25 | Transaction in Own Shares |
| 24 Jul 2026 | 11:25:35 | Holding(s) in Company |
| 23 Jul 2026 | 15:21:01 | Holding(s) in Company |
| 18 Mar 2026 | 2025 Annual Report and Accounts | |
| 19 Mar 2025 | 2024 Annual Report and Accounts | |
| 22 Mar 2024 | 2023 Annual Report and Accounts |
Hikma Pharmaceuticals plc is a global pharmaceutical company that develops, manufactures, and markets a wide range of generic, specialty, and branded medications. Its operations are divided into three main segments: Injectables, which supplies hospitals with generic and specialty injectable products; Branded, which offers branded generics and in-licensed patented products primarily in the MENA region; and Hikma Rx, which provides oral and respiratory generic products to the North American retail market. Hikma operates manufacturing facilities and R&D hubs across North America, Europe, and the MENA region, serving healthcare providers and patients in over 50 countries.
| 20 Jul 2026 |
| 09:22:01 |
| Transaction in Own Shares |
| 16 Jul 2026 |
| Citi starts Hikma at 'buy' with strategy reset offering compelling entry point |
| 19 Mar 2026 | ii view: Hikma Pharmaceuticals injects big dose of caution |
| 17 Mar 2026 | FTSE 100 gains as defensive names rally |
| 13 Mar 2026 | 3 UK mid-cap stocks for growth and solidity on the cheap |
| 2 Mar 2026 | European stocks sink amid Middle East uncertainty |
| 26 Feb 2026 | Hikma tumbles on disappointing outlook |
| 20 Jul 2026 |
| 09:22:01 |
| Transaction in Own Shares |
| 16 Jul 2026 |
| Citi starts Hikma at 'buy' with strategy reset offering compelling entry point |
| 19 Mar 2026 | ii view: Hikma Pharmaceuticals injects big dose of caution |
| 17 Mar 2026 | FTSE 100 gains as defensive names rally |
| 13 Mar 2026 | 3 UK mid-cap stocks for growth and solidity on the cheap |
| 2 Mar 2026 | European stocks sink amid Middle East uncertainty |
| 26 Feb 2026 | Hikma tumbles on disappointing outlook |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £202.12bn | +0.2% | |
| £615m | +0.4% | |
| £318m | +0.4% | |
| £317m | -0.4% | |
| £231m | +0.2% | |
HIKHikma Pharmaceuticals PLC | — | -0.2% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £202.12bn | +0.2% | |
| £615m | +0.4% | |
| £318m | +0.4% | |
| £317m | -0.4% | |
| £231m | +0.2% | |
HIKHikma Pharmaceuticals PLC | — | -0.2% |